EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

On-treatment viral factors affect subsequent hepatitis B surface antigen seroclearance in patients treated with nucleos(t)ide analogs for > 10 years

Tetsuya Hosaka iD, Hayato Hikita iD, Yuki Tahata, Ryoko Yamada, Kazuhiro Murai, Masanori Miyazaki, Hisashi Ishida, Atsushi Hosui, Ryotaro Sakamori, Nobuyuki Tatsumi, Yoshinori Doi, Kazuyoshi Ohkawa und 17 weitere

Journal of Gastroenterology · 2026

DOI: 10.1007/s00535-026-02415-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastroenterology, 2026. Verfasst von Tetsuya Hosaka und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, The University of Osaka Graduate School of Medicine, Suita, Japan. Hauptthemen laut MEDLINE: Hepatitis B Surface Antigens, Hepatitis B, Chronic, Antiviral Agents, Nucleosides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Ministry of Health, Labour and Welfare, The University of Osaka.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Long-term nucleos(t)ide analog (NUC) treatment improves the outcomes of patients with chronic hepatitis B virus (HBV) infection. However, only a limited number of patients treated with NUC can achieve hepatitis B surface antigen (HBsAg) seroclearance, the so-called “functional cure.” However, it remains unclear how on-treatment viral factors affect HBsAg seroclearance during long-term NUC treatment. We aimed to investigate whether the baseline and on-treatment HBV markers can predict HBsAg seroclearance and reduction in patients treated with long-term NUC treatment.

Methods

This study included two independent cohorts consisting of 843 patients in the derivation cohort and 1781 patients in the validation cohort.

Results

HBsAg seroclearance was infrequent (3.7–6.2%), with annual rates of 4–10/1,000 person-years in the derivation and validation cohorts. In baseline hepatitis B e-antigen (HBeAg)-positive patients, early on-treatment HBeAg loss strongly predicted subsequent HBsAg seroclearance and a reduction of < 10 IU/mL, whereas delayed or absent HBeAg loss rarely followed HBsAg seroclearance. A simple predictive model for HBsAg seroclearance based on earlier HBeAg loss, sex, and age was developed (SLOPES50). In baseline HBeAg-negative patients, low baseline or on-treatment HBsAg levels (< 100 IU/mL) were key predictors of HBsAg seroclearance or a reduction of < 10 IU/mL. Landmark analysis and time-dependent Cox regression analyses confirmed these associations in both cohorts. A substantial number of patients remained HBsAg ≥ 100 even after 15 years of NUC treatment in both cohorts.

Conclusions

Functional cure during prolonged NUC treatment of > 10 years depends on early virological responses in both HBeAg-positive and HBeAg-negative patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B Surface AntigensHepatitis B, ChronicAntiviral AgentsNucleosidesHumansHepatitis B e AntigensFemaleMaleMiddle AgedAdultHepatitis B virusTreatment OutcomeTime FactorsCohort StudiesDNA, Viral

Stichwörter der Autor:innen

Functional cureHBeAgHBsAg seroclearanceNucleos(t)ide analogs

Substanzen

Hepatitis B Surface AntigensAntiviral AgentsHepatitis B e AntigensNucleosidesDNA, Viral

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, The University of Osaka Graduate School of Medicine, Suita, Japan.
  • Department of Hepatology, Toranomon Hospital, Tokyo, Japan.
  • Department of Gastroenterology and Hepatology, The University of Osaka Graduate School of Medicine, Suita, Japan. hikita@gh.med.osaka-u.ac.jp.
  • Department of Gastroenterology, Osaka Keisatsu Hospital, Osaka, Japan.
  • Department of Gastroenterology and Hepatology, Ikeda Municipal Hospital, Ikeda, Japan.
  • Department of Gastroenterology and Hepatology, Osaka Rosai Hospital, Sakai, Japan.

ORCID-Profile: Tetsuya Hosaka, Hayato Hikita

Förderung

  • Japan Agency for Medical Research and Development
  • Ministry of Health, Labour and Welfare
  • The University of Osaka

Zitieren

APA

Hosaka, T., Hikita, H., Tahata, Y., Yamada, R., Murai, K., Miyazaki, M., Ishida, H., Hosui, A., Sakamori, R., Tatsumi, N., Doi, Y., Ohkawa, K., Egawa, S., Nawa, T., Nozaki, Y., Imanaka, K., Nakahara, M., Sakakibara, M., Yakushijin, T., …, & Takehara, T. (2026). On-treatment viral factors affect subsequent hepatitis B surface antigen seroclearance in patients treated with nucleos(t)ide analogs for > 10 years. Journal of Gastroenterology. https://doi.org/10.1007/s00535-026-02415-3

Vancouver

Hosaka T, Hikita H, Tahata Y, Yamada R, Murai K, Miyazaki M, et al. On-treatment viral factors affect subsequent hepatitis B surface antigen seroclearance in patients treated with nucleos(t)ide analogs for > 10 years. Journal of Gastroenterology. 2026. doi:10.1007/s00535-026-02415-3

BibTeX
@article{Hosaka2026,
  author = {Hosaka, Tetsuya and Hikita, Hayato and Tahata, Yuki and Yamada, Ryoko and Murai, Kazuhiro and Miyazaki, Masanori and Ishida, Hisashi and Hosui, Atsushi and Sakamori, Ryotaro and Tatsumi, Nobuyuki and Doi, Yoshinori and Ohkawa, Kazuyoshi and Egawa, Satoshi and Nawa, Takatoshi and Nozaki, Yasutoshi and Imanaka, Kazuho and Nakahara, Masanori and Sakakibara, Mitsuru and Yakushijin, Takayuki and Yoshida, Yuichi and Ogawa, Hiroyuki and Usui, Takeo and Matsumoto, Kengo and Maesaka, Kazuki and Shirai, Kumiko and Makino, Yuki and Saito, Yoshinobu and Kodama, Takahiro and Takehara, Tetsuo},
  title = {On-treatment viral factors affect subsequent hepatitis B surface antigen seroclearance in patients treated with nucleos(t)ide analogs for > 10 years},
  journal = {Journal of Gastroenterology},
  year = {2026},
  doi = {10.1007/s00535-026-02415-3}
}
Kostenlos starten →